4.2 Review

Update Breast Cancer 2019 Part 4-Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer

期刊

GEBURTSHILFE UND FRAUENHEILKUNDE
卷 79, 期 10, 页码 1079-1089

出版社

GEORG THIEME VERLAG KG
DOI: 10.1055/a-1001-9925

关键词

breast cancer; adjuvant; neoadjuvant; chemotherapy; antihormone therapy; multigene tests

资金

  1. Hexal
  2. PRAEGNANT network - Pfizer
  3. Celgene
  4. Daiichi Sankyo
  5. Roche
  6. Merrimack
  7. Eisai
  8. AstraZeneca
  9. Novartis

向作者/读者索取更多资源

The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the use of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据